Health Condition 1: L910- Hypertrophic scar
Conditions
Interventions
Intervention1: Intralesional Injection Insulin: Patients will be given intralesional short acting insulin at a dose of 10 IU/cm3 at an interval of 4 weeks for 4 months
Control Intervention1: Intralesi
Sponsors
Dr.Jashanpreet Kaur
Eligibility
Inclusion criteria
Inclusion criteria: Age 18 to 60 years Both male and female Clinical diagnosis of keloid equal to more than 3 months duration Keloid of size between 1 to 10 cubic centimeters. Willing to provide informed consent and comply with follow-up
Exclusion criteria
Exclusion criteria: -Age less than 18 or more than 60 years -Keloid of size more than 10 cubic centimeters. -Diabetic patients -Individuals receiving insulin or oral hypoglycemic drugs -Pregnant or lactating female -Immunocompromised patients -Patients on immunosuppressive drugs or systemic corticosteroids within last 3 months -Patients with evidence of bone marrow suppression including leukopenia,thrombocytopenia or anemia -Active infection or ulceration over lesion -Recent keloid treatment within last 8 weeks -Keloids on mucosa, eyelids or sites unsafe for injection -Coagulopathy or bleeding disorder -Hypersensitivity to study drugs -Individuals unwilling or unable to comply with the follow up schedule
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the clinical efficacy of Intralesional Insulin vs Intralesional Triamcinolone acetonide vs Intralesional Triamcinolone acetonide + 5-Fluorouracil in management of keloid.Timepoint: Baseline, 4, 8, 12 and 16 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To study safety and tolerability of Intralesional Insulin vs Intralesional Triamcinolone Acetonide vs Intralesional Triamcinolone Acetonide + 5- Fluorouracil in management of keloid. Timepoint: 7 months | — |
Countries
India
Contacts
Public ContactDr Jashanpreet Kaur
Shri Bhausaheb Hire Government Medical College
Outcome results
None listed